Compare EVO & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | TNDM |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | Germany | United States |
| Employees | 4766 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | N/A | 2013 |
| Metric | EVO | TNDM |
|---|---|---|
| Price | $2.33 | $21.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 19 |
| Target Price | $7.00 | ★ $27.05 |
| AVG Volume (30 Days) | 123.2K | ★ 2.5M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | $7.13 | $12.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $2.40 | $10.00 |
| 52 Week High | $4.80 | $29.65 |
| Indicator | EVO | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 22.34 | 48.44 |
| Support Level | N/A | $19.48 |
| Resistance Level | $3.78 | $21.89 |
| Average True Range (ATR) | 0.10 | 1.40 |
| MACD | -0.11 | -0.38 |
| Stochastic Oscillator | 0.42 | 16.56 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.